Login to Your Account

Solid debut for gene therapy firm Audentes after pricing $75M IPO

By Jennifer Boggs
Managing Editor

Wednesday, July 20, 2016

In another promising sign for the gene therapy space, shares of Audentes Therapeutics Inc. received an encouraging welcome on Wall Street Wednesday after the firm priced a $75 million IPO, offering 5 million shares at $15 each, the midpoint of its proposed range.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription